Sentence examples for marrow blast number from inspiring English sources

[Table 2] No correlation was observed between pretherapeutic nucleosomal DNA levels and bone marrow blast number (r = 0.08; p = 0.722).

However, pretherapeutic nucleosomal DNA levels correlated inversely with bone marrow blast number after 16 days (r = -0.55; p = 0.012) and with the relative reduction of blast number from day 1 to 16 (r = 0.58; p = 0.007).

This hypothesis is further strengthened by our observation that the pretherapeutic levels and the AUC 2 4 of nucleosomal DNA, reflecting the immediate effect of therapy, were related to the percentual reduction of bone marrow blast number from days 1 to 16.

The bone marrow blast numbers at days 1 and 16 as well as their percentual changes were comparable in both response groups and could not discriminate between patients with complete remission and those with no response to therapy.

Baseline characteristics for the individual IPSS-R groups (low, intermediate, high), including IPSS score, transfusion burden, bone marrow blast count, number of cytopenias, platelet count, absolute neutrophil count, hemoglobin and cytogenetic complexity, were generally less favorable for patients in the higher IPSS-R risk groups.

The International Prognostic Scoring System (IPSS) identified three critical factors that influence survival and AML evolution: risk-based cytogenetic subgroups (good, intermediate and poor karyotypes), bone marrow blast percentage and the number of cytopenias.

The International Prognostic Scoring System (IPSS) is a widely used risk assessment tool [ 6] that stratifies patients into four risk groups based on cytogenetics, the percentage of bone marrow blasts, and the number of cytopenias [ 14].

Besides age there are several prognostic markers for AML patients that are used in clinical routine: Cytogenetics contain the most important prognostic information [ 5- 7], as does the blast number in the bone marrow: High amounts of bone marrow blasts before therapy are associated with adverse outcome [ 8] as well as incomplete elimination during the course of chemotherapy [ 9].

ELN response was achieved in 21.0% of the 371 patients (CI95% 17.0 25.5) and did not depend on bone marrow blast cell percentage.

Furthermore, FLT3 expression showed a weak but significant correlation with bone marrow blast counts (r = 0.36, p = 0.049).

*Bone marrow blast percentage.